Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$442.96
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
330.3
2026-03-01
M2 Money Supply
$22.7T
2026-03-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 101.8; M2 money supply is $22.7T; CPI index stands at 330.3.
SWOT Analysis — VRTX
Inflationary BoomStrengths
Net Income: $4.0B (+838.1% YoY) — Profit grew 838% — the company kept more of each dollar earned.
Operating Cash Flow: $3.6B (+837.2% YoY) — Operating cash flow grew 837% — the business generated more cash from day-to-day operations.
EPS (Diluted): $15.32 (+836.5% YoY) — Earnings per share rose 837% — each share earned more.
Revenue: $2.5B (+46.2% YoY) — Revenue grew 46% — the company sold more goods or services than the prior year.
Total Assets: $25.6B (+13.8% YoY) — Total assets grew 14% — the company's resource base expanded.
Weaknesses
R&D spending is 123% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
No significant threats flagged.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Net Income
$4.0B
was -$535.6M
Profit grew 838% — the company kept more of each dollar earned.
Operating Cash Flow
$3.6B
was -$492.6M
Operating cash flow grew 837% — the business generated more cash from day-to-day operations.
EPS (Diluted)
$15.32
was $-2.08
Earnings per share rose 837% — each share earned more.
Revenue
$2.5B
was $1.7B
Revenue grew 46% — the company sold more goods or services than the prior year.
Total Assets
$25.6B
was $22.5B
Total assets grew 14% — the company's resource base expanded.
Risk Flags
0 high · 0 medium · 1 low- ○ Low
R&D spending is 123% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade VRTX
Links open broker research pages. Not an endorsement or recommendation.
Research VERTEX PHARMACEUTICALS INC / MA
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.